Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Blum Study
NCT02410902Phase 3Completed
- Sponsor
- Curemark
- Start
- May 2015
- Primary completion
- Dec 2017
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of CM-AT in Autism Spectrum Disorder (ASD), sponsored by Curemark. Started May 2015; status: completed.
02
Drugs
CM-AT
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02410902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02410902.